All About Multiple Sclerosis

More MS news articles for March 2004

Liver injury associated with the beta-interferons for MS: a comparison between the three products

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14981183&dopt=Abstract

Neurology. 2004 Feb 24;62(4):628-31
Tremlett HL, Yoshida EM, Oger J.
Department of Medicine, Division of Neurology, Vancouver Hospital & Health Sciences Center, University of British Columbia, Vancouver, BC, Canada

A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a beta-interferon (IFNbeta) product in British Columbia, Canada was performed between 1995 and 2001.

Overall, 36.9% (243/659) of patients developed new elevations of alanine aminotransferase.

All the IFNbetas caused elevated aminotransferase levels compared with pretreatment levels (p < 0.005) and were higher than reported in clinical trials.

Their relative effect on aminotransferases can be approximated as IFNbeta-1b(subcutaneous [SC]) = IFNbeta-1a(SC) > IFNbeta-1a(IM).